- Home
- SNCR vs AVTX Comparison
SNCR vs AVTX Comparison
Compare SNCR & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNCR
- AVTX
- Stock Information
- Founded
- SNCR 2000
- AVTX 2011
- Country
- SNCR United States
- AVTX United States
- Employees
- SNCR N/A
- AVTX N/A
- Industry
- SNCR EDP Services
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- SNCR Technology
- AVTX Health Care
- Exchange
- SNCR Nasdaq
- AVTX Nasdaq
- Market Cap
- SNCR 83.1M
- AVTX 90.0M
- IPO Year
- SNCR 2006
- AVTX 2015
- Fundamental
- Price
- SNCR $6.63
- AVTX $8.95
- Analyst Decision
- SNCR Strong Buy
- AVTX Strong Buy
- Analyst Count
- SNCR 1
- AVTX 7
- Target Price
- SNCR $13.00
- AVTX $31.00
- AVG Volume (30 Days)
- SNCR 89.0K
- AVTX 306.4K
- Earning Date
- SNCR 08-11-2025
- AVTX 08-07-2025
- Dividend Yield
- SNCR N/A
- AVTX N/A
- EPS Growth
- SNCR N/A
- AVTX N/A
- EPS
- SNCR N/A
- AVTX N/A
- Revenue
- SNCR $171,870,000.00
- AVTX $441,000.00
- Revenue This Year
- SNCR $2.07
- AVTX N/A
- Revenue Next Year
- SNCR $5.42
- AVTX N/A
- P/E Ratio
- SNCR N/A
- AVTX N/A
- Revenue Growth
- SNCR 2.54
- AVTX N/A
- 52 Week Low
- SNCR $6.00
- AVTX $3.39
- 52 Week High
- SNCR $15.46
- AVTX $16.00
- Technical
- Relative Strength Index (RSI)
- SNCR 42.96
- AVTX 70.91
- Support Level
- SNCR $6.35
- AVTX $8.29
- Resistance Level
- SNCR $8.15
- AVTX $9.88
- Average True Range (ATR)
- SNCR 0.43
- AVTX 0.94
- MACD
- SNCR -0.10
- AVTX 0.08
- Stochastic Oscillator
- SNCR 24.23
- AVTX 74.66
About SNCR Synchronoss Technologies Inc.
Synchronoss Technologies Inc is a provider of white-label cloud, messaging, digital and network management solutions that enable its customers to keep subscribers, systems, networks and content in sync. The Synchronoss Personal CloudTM solution is designed to create an engaging and trusted customer experience through ongoing content management and engagement. The Synchronoss Personal CloudTM platform is a secure and scalable, white-label platform that allows its customers' subscribers to backup and protect, engage with, and manage their personal content. The company derives revenue from subscriptions and transaction-based fees. A majority of the firm's revenue is generated in the United States, and the rest is from countries across the world.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).